Bausch Health Companies Inc.

Bausch Health Companies Inc. is a global, diversified pharmaceutical company dedicated to enriching lives by delivering better health outcomes. Headquartered in Laval, Quebec, Canada, with U.S. headquarters in Bridgewater, New Jersey, the company develops, manufactures, and markets a broad range of pharmaceutical products and medical devices.

The company's portfolio spans key therapeutic areas including gastroenterology, hepatology, neuroscience, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Its offerings include branded and generic pharmaceuticals, over-the-counter products, and medical devices. Key operating segments include Salix (gastrointestinal products), International, Solta Medical (medical aesthetics), Diversified Products (neurology, generics, dentistry), and a controlling interest in Bausch + Lomb (eye health and vision care).

Led by CEO Thomas J. Appio, Bausch Health recently reported strong financial results for Q1 2026, with a 12% year-over-year increase in total consolidated revenue and a 27% increase in adjusted EBITDA. The Salix and Solta Medical segments were notable contributors to this growth. The company continues to focus on its product pipeline, including advancing the investigational hepatitis drug larsucosterol, and recently launched CABTREO® for acne vulgaris in Canada.